lobbying_activities: 1226822
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1226822 | 5fd35b50-d60f-48f6-ab39-af48131b6a67 | Q1 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2012 | first_quarter | PHA | S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans. | HOUSE OF REPRESENTATIVES,SENATE | 190000 | 0 | 0 | 2012-04-13T16:13:03.630000-04:00 |